Company Sells 100,000th Pulse Oximetry Unit
NEW YORK, Oct. 22 /PRNewswire-FirstCall/ -- SPO Medical Inc. (OTC Bulletin Board: SPOM), a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices, today announced that is has sold its 100,000th pulse oximetry unit. This sales milestone has been achieved within three years of the company's first introduction of the commercial product.
The bulk of the 100,000 units sold include the patented technology of PulseOx 5500(TM) and the PulseOx 7500(TM), a new product that was commercially launched during the second quarter of 2007. First introduced at the end of 2004, the PulseOx 5500(TM) is a spot check finger monitor for the medical market and is sold primarily to homecare users as well as to hospitals, physicians and emergency care facilities to monitor heart rate and blood oxygenation levels. The PulseOx 7500(TM) device is sold to physicians and sleep clinics primarily for pre-screening of sleep apnea; a medical condition with fast growing awareness throughout the industrialized world.
SPO Medical intends to announce two new professional oximetry devices this year for the hospital and physician markets. These new products will be first shown during mid-November at the annual Medica Exposition in Dusseldorf, Germany which is the world's largest medical international trade fair for supplies of medical devices; this will be followed by the American Association for Respiratory Care (AARC) International Respiratory Congress in Florida in December of this year.
"We are pleased to announce this major sales milestone and look forward to further growing the company with the addition of new products expanding our technology to a number of market applications" said Michael Braunold, President and CEO of SPO Medical Inc. "The launch of two new oximetry devices later this year is a further testament to our commitment and implementation of our strategy of introducing innovative products to the marketplace."
For additional details of SPO Medical' attendance at commercial forums, please visit our web site at http://www.spomedical.com
About SPO Medical
SPO Medical (SPOM) a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices to capture life-saving and life-enhancing information within four key markets: medical care; home and remote-care; sports and wellness; and safety and security. Its patented technology uses information gathered from the reflectance of light on the human blood stream, in a non-invasive manner, to monitor key vital signs. The Company distributes its products through a network of distributors and also licenses its technologies to appropriate client corporations for commercialization and distribution. For more information, visit http://www.spomedical.com.
This press release contains forward-looking statements that involve substantial uncertainties and risks. These forward-looking statements are based upon our current expectations, estimates and projections about our business and our industry, and that reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including but not limited to, changes in economic conditions generally and the medical devices market specifically, changes in technology, legislative or regulatory changes that affect us, the availability of working capital, changes in costs and the availability of goods and services, the introduction of competing products, delays in planned product launches, changes in our operating strategy or development plans, our ability to attract and retain qualified personnel, the possible fluctuation and volatility of our operating results, financial condition and stock price and the risks and uncertainties discussed under the heading "Risk Factors" in Item 1 of our Annual Report on Form 10-KSB for the fiscal year ended December 31, 2006. We undertake no obligation to revise or update any forward-looking statement for any reason.
SPO Medical Contact: Seventh Circle Consulting Contact:
Michael Braunold, CEO Christine J. Petraglia
|SOURCE SPO Medical Inc.|
Copyright©2007 PR Newswire.
All rights reserved